Reactive infectious mucocutaneous eruption (RIME) is a rare pediatric condition characterized by severe mucositis, minimal cutaneous involvement, and an infectious rather than drug-induced etiology. Mycoplasma pneumoniae (M. Pneumoniae) represents the most frequently identified trigger, although an increasing number of alternative pathogens have been reported. Its clinical overlap with Stevens–Johnson syndrome (SJS) makes early recognition difficult. We reviewed literature data on the topic and described our center’s experience with three pediatric cases of M. pneumoniae-associated RIME. Medical records, laboratory results, and imaging were systematically analyzed. All patients were male, aged 2 to 12 years and originated from rural communities. Etiologic confirmation was achieved via M. pneumoniae IgM serology and/or polymerase chain reaction. Clinical exam modifications included multi-site mucositis (oral, ocular, genital) with variable skin involvement: absent in one case, a solitary palm ulcer in another, and widespread rash in the third. One patient required two hospitalizations within a six-month interval, confirming the possible relapsing phenotype of RIME. Another patient developed pneumonia, sepsis, and systemic inflammation. All received macrolide therapy, antifungals, mucosal supportive care, and systemic management as indicated. Recovery occurred within 10–21 days, with one patient exhibiting skin hyperpigmentation. These cases illustrate the heterogeneity of RIME, emphasize the importance of prompt recognition, etiology confirmation, and multidisciplinary management. RIME is a rare clinical condition in pediatric population, an uncommon but significant mucocutaneous clinical entity, important to be acknowledged by clinicians as a complication and/or extra-pulmonary manifestation of M. pneumoniae infection.
Inborn errors of immunity (IEIs) encompass a heterogeneous group of more than 550 genetic conditions with variable ages of onset. A significant proportion of IEI arises from genetic variants that may not yet be fully elucidated or recorded in existing genomic databases. Molecular diagnoses are achieved in approximately 15–35% of IEI cases, yet in only 9–20% of individuals with predominant antibody deficiencies, particularly in adult cohorts. We aimed to evaluate whole genome sequencing (WGS) diagnostic yield in adults suspected to have IEI. Clinical assessments of the patients were carried out at tertiary medical institutions in Timisoara and Bucharest, Romania. The study cohort included a consecutive series of 21 adult patients (aged 19–60 years) with IEI phenotype, who underwent genetic analysis, using WGS as the first diagnostic approach. A definitive molecular diagnosis was confirmed in only 9.5% (2/21) of the participants, in LRBA and BTK genes. Variants of uncertain significance (VUS) were detected in three patients (13.6%) in TNFRSF13B, COPA, GATA2 genes. For about half of the cohort the onset of the disease was noted in childhood. WGS as a first-line diagnostic strategy in a cohort of adults with IEI yielded a low diagnostic rate. There were significant delays in genetic diagnosis, as half of the cohort experienced childhood-onset symptoms. Results suggest that adult IEI diagnosis remains challenging, necessitating functional studies and longitudinal re-evaluation of genomic data.